One potential mechanism through which female steroidal hormones can act upon ER/PR-negative (tumor) cells is via Receptor Activator of Nuclear factor Kappa(κ)-B (RANK) and its ligand, RANKL. Here, TNFSF11 is linked to neoplasm.